Burlington, Mass. – October 30, 2026 -- Azenta (Nasdaq: AZTA) has secured an exclusive license to Elegen Corp.'s cell-free DNA synthesis platform and acquired SynPlexity Inc., two moves aimed at expanding the gene synthesis and discovery capabilities of its GENEWIZ business.